Skip to main content


Fig. 1 | Clinical Epigenetics

Fig. 1

From: Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

Fig. 1

Interaction between tumour and immune cells. T cell stimulation is driven by antigens and requires a coordinated participation of several other receptors and molecules expressed on the T cell surface and antigen-presenting cells (APCs) or tumour cells. HDACi and/or DNMTi can inhibit different signalling pathways involved in adaptive immune responses, enhancing antitumour effects by combination with immune checkpoint inhibitors

Back to article page